Pushpendra Hirapara

Congratulations 👏 . ✨ Dr. Sudeep Gupta and team @TataMemorial deliver the first phase III trial showing OS benefit with carboplatin in TNBC (JCO 2025, n=717). Overall (ITT population): 📈 5-yr EFS: 70.7% vs 64.1% (HR 0.80, p = 0.081) 💫 5-yr OS: 74.4% vs 66.8% (HR 0.74, p = 0.029) ⭐ pCR: 54.5% vs 40.3% (p < 0.001) Premenopausal subgroup: 🚀 5-yr EFS: 75.0% vs 59.6% (HR 0.61, p = 0.003) 🏆 5-yr OS: 78.2% vs 64.6% (HR 0.57, p = 0.002) In postmenopausal TNBC, carboplatin offered no additional EFS or OS benefit, underscoring the need for biology-driven rather than intensity-driven approaches in this group. 🌍 A shining example of an investigator-initiated LMIC trial — proving that world-class, practice-shaping oncology research can emerge from India. 🇮🇳 @ICMRDELHI @CRI_ACTREC ascopubs.org/doi/10.1200/JC…

@drakhilkapoor1 @VanitaNoronha @bkmmishra @TMC_Varanasi @NarjustFlorezMD @Bipinesh @dranuj16 @ASCO @IASLC @DrSanjayPopat @DrJNaidoo @LungConnectIN @myESMO @oncodaily @SuyogCancer @JenniferCKing @StephenVLiu Many many congratulations 👏💐

Got Young Investigator Award at #WCLC for project aimed to provide insights into the Microbiome of Indian Lung Cancer patients receiving IO. Thanks to my mentors Kumar Sir, @VanitaNoronha Maam and @bkmmishra Sir. @TMC_Varanasi @NarjustFlorezMD @Bipinesh @dranuj16

🫘🤰Hemodialysis in Pregnancy kidneynews.org/view/journals/…

#ASCO 2021 We reported long-term result of SABR in operable stage IA NSCLC: 91% OS at 3-y and 87% at 5-y, nearly identical for the propensity-matched contemporary VATS surgery. SABR remains promising for such cases and MDT is crucial. @MDAndersonNews @ACKoongMDPhD @PercyLeeMD

Durvalumab survival benefit after CTRT in NSCLC confirmed at 5 years. HR for OS 0.72 with Survival @60m of 43% vs 33% #Immunotherapy #ASCO21

Squamous esophageal carcinoma achieve better survival when immunotherapy is added to chemotherapy in two Ph III clinical trials presented at #ASCO2021 @OncoAlert

@ANI ?AIIMS...Let him have expert opinion at Ramdev-Balkrushna's Patanjali...?? Is allopathy stupid science only for common people and useful for ministers???

Union Education Minister Dr Ramesh Pokhriyal Nishank admitted to AIIMS due to post COVID complications today: AIIMS officials (File pic)

Join Us for the Twitter Storm at 5pm #ArrestQuackRamdev

Completely support the step taken by @IMAIndiaOrg against @yogrishiramdev #ArrestRamdev #ArrestQuackRamdev

@kartikApurohit @Drpvc Patients post chemotherapy needs to wait till counts came in normal range (especially neutrophils, lymphocytes, platelets), those to be planned for radiotherapy can go for vaccines provided their count within normal range, same for hormonal therapy provided normal counts

@Drpvc @RadonPushpendra For solid malignancy we have given covishield. Haven't given to patients on immunosuppressive therapy. Theorotically killed vaccine can be given to them with suboptimal response. All based on level C evidence.

Sir What about vaccine in Patients with Cancer on chemotherapy? @RadonPushpendra @kartikApurohit

@narendramodi Y Farmers are paid money in cash in Mandi by govt esp. for crops like Afim/opium... Dreaming India with max.. Cashless transaction...

@arunjaitley kindly arrange some laws for consumers who wants to pay cashless , seller can't deny if amt is >500Rs...

Dipawali ki shubhkamnae....

How does radiation therapy work against cancer? We have the details: 1.usa.gov/1GKm3RI

Prostate Cancer Screening Rates After the 2012 USPSTF Recommendation bit.ly/1QmfAm6 #JCO #PCSM

Today is World #NoTobacco Day! Let's try to end the trade of tobacco products! Learn more: bit.ly/1BqIaHn

Adding jaw tracking to IMRT and VMAT can reduce spinal cord dose, according to #PRO. ow.ly/CT1gN

"@ASCO: Vitamin D Deficiency in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab bit.ly/1qkg61Y #JCO #lymsm"

#RedJournal article says accelerated partial breast irradiation has acceptable long-term local control and toxicity. ow.ly/CS2Vk